Merck Serono announced today that its product, Rebif (interferon beta-1a) is celebrating its 10th anniversary this year. Since receiving approval for the treatment of relapsing-remitting multiple sclerosis 10 years ago in the European Union, as well as in Canada and Switzerland, Rebif has become a foundation therapy for MS.

rebif.jpg

Elmar Schnee, President of Merck Serono said: “The introduction of Rebif(R) was a significant advancement in the treatment of MS. We will continue our long-term commitment to improving the lives of people with MS through the development of additional therapeutic options.”

Merck Serono is continuing to advance the treatment of MS with its research and development pipeline. With regulatory filing expected in 2009, the company’s cladribine tablets (currently in Phase III trials) could potentially become the first oral therapy for MS. In October 2007, Merck Serono announced the identification of gene DPP6 at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Prague. Bernhard Kirschbaum, Executive Vice President Research at Merck Serono said: “…We believe that our genetics research platform provides a solid basis for the discovery of the treatments of the future.” The press release noted key milestones for Rebif.

By Shilz

Source: PR Newswire Europe
Image Source:Blogfarmacias.com

Advertisements